LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

Kodu・Aktsiate loetelu・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Suletud

SektorTervishoid

18.51 -0.16

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.76

Max

18.62

Põhinäitajad
By Trading Economics
Sissetulek	-607K -51M
Müük	-28M 100M
Aktsiakasum	-0.46
Kasumimarginaal	-51.215
Töötajad	1,784
EBITDA	4.1M -44M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+73.35% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-308M 2.1B
Eelmine avamishind	18.67
Eelmine sulgemishind	18.51

Uudiste sentiment

By Acuity

30%

70%

59 / 344 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. mai 2026, 21:33 UTC

Tulu

Correction to Salesforce 1Q Sales, Profit Rise Article

27. mai 2026, 21:00 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare Agrees to Buy The College of Health Care Professions

27. mai 2026, 20:18 UTC

Tulu

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27. mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27. mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27. mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27. mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27. mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27. mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27. mai 2026, 21:29 UTC

Kuumad aktsiad

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27. mai 2026, 21:08 UTC

Tulu

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27. mai 2026, 21:02 UTC

Tulu

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27. mai 2026, 20:59 UTC

Omandamised, ülevõtmised, äriostud

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27. mai 2026, 20:55 UTC

Tulu

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. mai 2026, 20:48 UTC

Tulu

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27. mai 2026, 20:45 UTC

Tulu

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27. mai 2026, 20:34 UTC

Omandamised, ülevõtmised, äriostud

Webster Financial Stockholders Approve Sale to Banco Santander

27. mai 2026, 20:32 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27. mai 2026, 20:32 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27. mai 2026, 20:32 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27. mai 2026, 20:30 UTC

Tulu

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27. mai 2026, 20:30 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27. mai 2026, 20:22 UTC

Tulu

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. mai 2026, 20:16 UTC

Tulu

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. mai 2026, 20:13 UTC

Tulu

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27. mai 2026, 20:13 UTC

Tulu

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27. mai 2026, 20:13 UTC

Tulu

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27. mai 2026, 20:12 UTC

Tulu

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27. mai 2026, 20:12 UTC

Tulu

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

73.35% tõus

12 kuu keskmine prognoos

Keskmine 32.4 USD 73.35%

Kõrge 44 USD

Madal 21.6 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Zai Lab Ltd ADR aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

59 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.